@article {HAYASHI2193, author = {KAZUMI HAYASHI and MIHO TAMURA and EIJIRO NAGASAKI and YUKIKO YOSHII and TAKAYUKI ISHIGAKI and TAKASHI KAZAMA and MAKIKO KAMIO and HIROKO NOGI and YASUO TORIUMI and HIROSHI TAKEYAMA and SHINGO YANO}, title = {A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer}, volume = {41}, number = {4}, pages = {2193--2195}, year = {2021}, doi = {10.21873/anticanres.14994}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Since January 2020, coronavirus disease (COVID-19) cases have been confirmed in Japan, and the number of patients with COVID-19 has been increasing. Two emergency declarations have been made previously and one is currently in effect. Based on our experience of a situation that could affect cancer treatment, this study retrospectively examined the correlation between perioperative anticancer therapy and COVID-19 incidence in patients with breast cancer. Patients and Methods: Patients who underwent perioperative anticancer therapy for breast cancer at our hospital from February 2020 to February 2021 were included in this study. The presence or absence of COVID-19, timing of anticancer drug initiation, and clinical data were collected. Results: No cases of COVID-19 were diagnosed in patients receiving perioperative anticancer therapy at our hospital. Conclusion: Regimen modification, active use of supportive care, and patient lifestyle were factors reducing the incidence of COVID-19.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/41/4/2193}, eprint = {https://ar.iiarjournals.org/content/41/4/2193.full.pdf}, journal = {Anticancer Research} }